<DOC>
	<DOCNO>NCT02629523</DOCNO>
	<brief_summary>Treatment efficacy afatinib assess patient lung cancer harbor EGFR mutation detect circulate tumor DNA .</brief_summary>
	<brief_title>Afatinib Lung Cancer With EGFR Mutation From Circulating Tumor DNA</brief_title>
	<detailed_description>Obtaining Tumor tissue cytology sample always available patient lung cancer . Recently , study show circulate tumor DNA use suitable substitute mutation analysis . The sensitivity EGFR mutation test use circulate tumor DNA report range 65.7 % ( 10 ) 75 % ( 11 ) , high specificity positive predictive value . In trial , treatment efficacy afatinib assess patient NSCLC harbor EGFR mutation detect circulate tumor DNA .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>1 . Stage IIIB IV lung cancer diagnose radiologically without pathologic diagnosis 2 . Age &gt; 18 yearold 3 . ECOG performance status 0~2 . 4 . Activating EGFR mutation ( G719X , exon 19 deletion , L858R , L861Q ) detect circulate DNA 5 . Any one follow criterion meet Unavailable fail pathologic/cytologic diagnosis Wild type fail EGFR test base tumor tissue No tumor sample available EGFR test 6 . Measurable lesion RECIST v1.1 7 . Females use adequate contraceptive measure , breast feeding must negative pregnancy test prior start dose evidence nonchild bear potential . 8 . Male patient willing use barrier contraception . 9 . Provision sign date , write informed consent prior study specific procedure , sample analysis 10 . Adequate organ function , define follow : Absolute neutrophil count ( ANC ) &gt; =1500/mm3 Platelet count &gt; = 75,000 /mm3 Serum creatinine &lt; 1.4 mg/dL AST ALT &lt; three time upper limit normal 1 . Prior exposure EGFRTKI . Prior chemotherapy permit . 2 . Previous concomitant malignancy site , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . 3 . Severe unstable medical condition history presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification â‰¥ 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior randomisation . 4 . Known preexist interstitial lung disease 5 . Any history presence poorly control gastrointestinal disorder could affect absorption study drug ( e.g . Crohn 's disease , ulcerative colitis , chronic diarrhoea , malabsorption ) 6 . Active hepatitis B infection ( define presence HepB sAg Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>